Enzo Biochem (ENZ) Reaches New 52-Week Low at $3.74

Share on StockTwits

Enzo Biochem, Inc. (NYSE:ENZ) shares reached a new 52-week low on Thursday . The company traded as low as $3.74 and last traded at $3.80, with a volume of 5285 shares trading hands. The stock had previously closed at $3.88.

Separately, ValuEngine upgraded Enzo Biochem from a “sell” rating to a “hold” rating in a research note on Monday, July 16th.

Hedge funds have recently bought and sold shares of the business. Schwab Charles Investment Management Inc. lifted its position in shares of Enzo Biochem by 20.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 214,867 shares of the medical research company’s stock valued at $1,178,000 after buying an additional 36,971 shares during the last quarter. Northern Trust Corp lifted its position in shares of Enzo Biochem by 5.5% in the first quarter. Northern Trust Corp now owns 509,752 shares of the medical research company’s stock valued at $2,793,000 after buying an additional 26,563 shares during the last quarter. BlackRock Inc. lifted its position in shares of Enzo Biochem by 0.9% in the first quarter. BlackRock Inc. now owns 3,679,834 shares of the medical research company’s stock valued at $20,165,000 after buying an additional 32,919 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Enzo Biochem by 1,767.9% in the first quarter. JPMorgan Chase & Co. now owns 165,964 shares of the medical research company’s stock valued at $910,000 after buying an additional 157,079 shares during the last quarter. Finally, Citadel Advisors LLC lifted its position in shares of Enzo Biochem by 74.4% in the first quarter. Citadel Advisors LLC now owns 98,080 shares of the medical research company’s stock valued at $538,000 after buying an additional 41,839 shares during the last quarter. Hedge funds and other institutional investors own 67.75% of the company’s stock.

About Enzo Biochem (NYSE:ENZ)

Enzo Biochem, Inc, an integrated diagnostic bioscience company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics.

Further Reading: Buyback For Investors Defined

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply